Press Releases

April 02, 2012
Cornerstone Pharmaceuticals announces presentations regarding its proprietary anticancer compound CPI-613 at 2012 Annual AACR Meeting

December 12, 2011
Cornerstone Pharmaceuticals’ cancer metabolism inhibitor, CPI-613, showing promise in Phase I trial for acute myeloid leukemia

October 26, 2011
Cornerstone Pharmaceuticals to present at the 9th Annual Discovery on Target Meetings in Boston

September 15, 2011
Cornerstone Pharmaceuticals publishes positive pre-clinical study results comparing its proprietary drug EmPAC™ to Taxol® in the Journal of Nanoscience and Nanotechnology

September 06, 2011
Cornerstone Pharmaceuticals announces FDA orphan drug designation of CPI-613 for patients with acute myeloid leukemia

July 25, 2011
Cornerstone Pharmaceuticals announces the Journal of Molecular Medicine’s publication of research showing selective inhibition of cancer cell energy metabolism with its novel lipoate derivative compounds

June 03, 2011
Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia

March 14, 2011
Cornerstone Pharmaceuticals Announces Positive Results of Emulsiphan Safety Study

November 05, 2010
Cornerstone Pharmaceuticals Awarded $490K in Grants Under QTDP Program

October 11, 2010
Cornerstone Pharmaceuticals Presents Interim Phase I Data at the European Society of Medical Oncology Annual Conference